Dermcidin-derived peptides for lung cancer diagnostics
US9321818B2 · kind B2 · utility
0Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2010 |
| Grant date | Apr 26, 2016 |
| Priority date | — |
| Expiry date | Nov 15, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/6851
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for diagnosis of non-small cell lung cancers by detection of endogenous peptides in exhaled breath condensate (EBC) are provided. Diagnostic peptides derived from dermcidin (DC) are provided. A specific dermcidin-derived peptide E-R11, having the sequence ENAGEDPGLAR (SEQ ID NO:2), is provided. E-R11 peptide levels in EBC, as measured by mass spectrometry (MS), are highly diagnostic of non-small cell lung cancers. A method for inhibiting growth of lung cancer cells by inhibiting DCD expression by RNA interference also is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.